Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection

Slides:

Advertisements

Similar presentations

Volume 60, Issue 4, Pages (October 2011)

Advertisements

Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine.

Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial) M. Yoshida, K. Muro, A. Tsuji,

Pascal Rischmann European Urology Supplements

Achieving the Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management Michael O’Leary European Urology Supplements

Fred Saad European Urology Supplements

Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials Pippa Newell, Augusto Villanueva, Josep M. Llovet

Renal Cell Carcinoma: Prognostic Factors and Patient Selection

Volume 53, Issue 5, Pages (May 2008)

European Urology Oncology

The Role of Residual Tumor Resection in Patients with Metastatic Renal Cell Carcinoma and Partial Remission following Immunochemotherapy Olaf A. Brinkmann,

New Research on Kidney Cancer: Highlights from Urologic and Oncologic Congresses in 2006 Jean-Jacques Patard, Eric Lechevallier, Belén Congregado Ruiz,

Volume 68, Issue 1, Pages (July 2015)

Hormone Therapy for Prostate Cancer: Exploring Current Controversies

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Giuseppe Di Lorenzo, Riccardo Autorino, Cora N. Sternberg

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Bladder Cancer: A Major Public Health Issue

Volume 66, Issue 2, Pages (August 2014)

What is New in Bladder Cancer Diagnosis and Management?

New Trends in Bladder Cancer Management

Volume 52, Issue 5, Pages (November 2007)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma Viktor Grünwald, Xun Lin, Daniel Kalanovic,

Treatment of Symptomatic Benign Prostatic Hyperplasia: Current and Future Clinical Practice in Europe – What is Really Happening? Bob Djavan European.

Counselling the Prostate Cancer Patient

Laurent Boccon-Gibod European Urology Supplements

Volume 74, Issue 3, Pages (September 2018)

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Volume 59, Issue 1, Pages (January 2011)

Volume 68, Issue 4, Pages (October 2015)

Richard C. Harkaway European Urology Supplements

Mammalian Target of Rapamycin Inhibitors in Clinical Practice: Case Reports of Everolimus in Renal Cell Carcinoma Sergio Bracarda, Alain Ravaud, Marino.

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

The Importance of Testosterone Control in Prostate Cancer

Jacques Irani European Urology Supplements

Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice Claus Roehrborn European Urology.

Neal Shore European Urology Supplements

Kidney Cancer: Highlights from 2006

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Bernard Escudier European Urology Supplements

Bladder Cancer: Highlights from 2006

George Blumenschein, MD, John V. Heymach, MD, PhD

Sergio Bracarda European Urology Supplements

Challenges and Opportunities in Hormone-Resistant Prostate Cancer

Christian Stief European Urology Supplements

Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma Fred Saad European Urology.

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Volume 51, Issue 6, Pages (June 2007)

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? Vincenzo Mirone

Axel Heidenreich European Urology Supplements

Profile of Silodosin European Urology Supplements

Stone Disease European Urology Supplements

European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why? Jean-Jacques Patard

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

Management of Prostate Cancer: Global Strategies

Treatment Options in Prostate Cancer Once Primary Therapy Fails

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Joaquim Bellmunt European Urology Supplements

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Integrating Patient Risk Profiles in the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) in Clinical Practice

Penile and Testicular Cancer: What's New in 2006?

New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer Noel W. Clarke European Urology Supplements

Jan Roigas European Urology Supplements

Axel Heidenreich European Urology Supplements

Update on the Medical Treatment of Metastatic Renal Cell Carcinoma

European Urology Oncology

Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma Guillermo de Velasco, Axel Bex, Laurence Albiges, Thomas Powles, Brian.

Presentation transcript:

Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection Jean-Jacques Patard European Urology Supplements Volume 7, Issue 9, Pages 601-609 (September 2008) DOI: 10.1016/j.eursup.2008.06.001 Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 1 Progression-free survival (PFS) by Memorial Sloan-Kettering Cancer Center risk group in patients treated with sunitinib or interferon-α in the first-line setting. European Urology Supplements 2008 7, 601-609DOI: (10.1016/j.eursup.2008.06.001) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 2 Progression-free survival (PFS) by Memorial Sloan-Kettering Cancer Center risk group in patients previously treated with cytokines in the sunitinib expanded-access study. European Urology Supplements 2008 7, 601-609DOI: (10.1016/j.eursup.2008.06.001) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 3 Progression-free survival (PFS) in sunitinib-treated patients according to the risk factors derived from a multivariate analysis (phase 3 trial comparing sunitinib to interferon-α). European Urology Supplements 2008 7, 601-609DOI: (10.1016/j.eursup.2008.06.001) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 4 Progression-free survival (PFS) in subgroups of patients previously treated with cytokines in the expanded-access study. European Urology Supplements 2008 7, 601-609DOI: (10.1016/j.eursup.2008.06.001) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 5 Treatment algorithm for metastatic renal cell carcinoma. IFN-α, interferon-α; IL-2, interleukin 2; mRCC, metastatic renal cell carcinoma; MSKCC, Memorial Sloan-Kettering Cancer Center; mTOR, mammalian target of rapamycin. European Urology Supplements 2008 7, 601-609DOI: (10.1016/j.eursup.2008.06.001) Copyright © 2008 European Association of Urology Terms and Conditions